Abstract
RNA interference (RNAi) has rapidly become a powerful tool for drug-target discovery and therapeutics. Cancer is an important application for RNAi therapeutics, since abnormal gene regulation is thought to contribute to the pathogenesis and maintenance of the metastatic phenotype of cancer. Many oncogenic genes present enticing therapeutic target possibilities for RNAi. Small interfering RNA (siRNA) and microRNA (miRNA) are potent and specific examples of RNAi are able to silence tumor-related genes and multiple oncogenic pathways and appear to be a rational approach to inhibit tumor growth. In subsequent in vivo studies, an appropriate animal model must be developed for a better evaluation of gene-silencing effects on tumors. How to evaluate the effect of siRNA and miRNA in an in vivo therapeutic model is also important. Bioluminescence imaging is an optical imaging method that can evaluate RNAi in vivo.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bass, B.L. (2000) Double-stranded RNA as a template for gene silencing. Cell 101, 235–238.
Mcmanus, M.T. and Sharp, P.A. (2003) Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 3, 737–747.
Shankar, P., Manjunath, N., and Lieberman, J. (2005) The prospect of silencing disease using RNA interference. JAMA 293, 1367–1373.
Leung, R.K., Whittaker, P.A. (2005) RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 107, 222–239.
Behlke, M.A. (2006) Progress towards in vivo use of siRNAs. Mol Ther 13, 644–670.
Dykxhoorn, D.M., Palliser, D., and Lieberman, J. (2006) The silent treatment: siRNAs as small molecule drugs. Gene Ther 13, 541–552.
Rayburn, E.R., Wang, H., and Zhang, R. (2006) Antisense-based cancer therapeutics: are we there yet? Expert Opin Emerg Drugs 11, 337–352.
Hagan, J.P. and Croce, C.M. (2007) MicroRNAs in carcinogenesis. Cytogenet Genome Res 118, 252–259.
Jiang, J., Gusev, Y., Aderca, I., Mettler, T.A., Nagorney, D.M., Brackett, D.J., Roberts, L.R., and Schmittgen, T.D. (2008) Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14, 419–427
Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297.
Osaki, M., Takeshita, F., and Ochiya, T. (2008) MicroRNA as biomarkers and therapeutic drugs in human cancer. Biomarkers 13, 658–670.
Minakuchi, Y., Takeshita, F., Kosaka, N., Sasaki, H., Yamamoto, Y., Kouno, M., Honma, K., Nagahara, S., Hanai, K., Sano, A., Kato, T., Terada, M., and Ochiya, T. (2004) Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 32:e109.
Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., Kato, T., Sano, A., and Ochiya, T. (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102, 12177–12182.
Honma, K., Iwao-Koizumi, K., Takeshita, F., Yamamoto, Y., Yoshida, T., Nishio, K., Nagahara, S., Kato, K., and Ochiya, T. (2008) RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 14, 939–948.
Takei, Y., Kadomatsu, K., Goto, T., and Muramatsu, T. (2006) Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer, 107, 864–873.
Vooijs, M., Jonkers, J., Lyons, S., and Berns, A. (2002) Cancer Res 62, 1862–1867.
Hoffman, R.M. (1999) Orthotopic transplant mouse models with green fluorescent protein-expressing cancer cells to visualize metastasis and angiogenesis. Cancer and Metastasis Reviews 17, 271–277.
Hoffman, R.M. (1999) Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17, 343–359.
Hoffman, R.M. (2002) In vivo imaging of metastatic cancer with fluorescent proteins. Cell Death Differ 9, 786–789.
Hoffman, R.M. (2005) Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods Mol Med 111, 297–322.
Nakanishi, H., Ito, S., Mochizuki, Y., and Tatematsu, M. (2005) Evaluation of chemosensitivity of micrometastases with green fluorescent protein gene-tagged tumor models in mice. Methods Mol Med 111, 351–362.
Hennig, R., Ventura, J., Segersverd, R., Ward, E., Ding, X.Z., Rao, S.M., Jovanovic, B.D., Iwamura, T., Talamonti, M.S., Bell, R.H. Jr, and Adrian, T.E. (2005) LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia 7, 417–425.
Contag, P.R., Olomu, I.N., Stevenson, D.K., and Contag, C.H. (1998) Bioluminescent indicators in living mammals. Nat Med 4, 245–247.
Rehemtulla, A., Stegman, L.D., Cardozo, S.J., Gupta, S., Hall, D.E., Contag, C.H., and Ross, B.D. (2000) Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2, 491–495.
Jenkins, DE, Oei, Y, Hornig, YS, Yu, S.F., Dusich, J., Purchio, T., and Contag, P.R. (2003) Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 20, 733–744.
Vooijs, M., Jonkers, J., Lyons, S., and Bernes, A. (2002) Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res 62, 1862–1867.
Lyons, S.K. (2005) Advances in imaging mouse tumor models in vivo. J Pathol 205,194–205.
Laurie, N.A., Gray, J.K., Zhang, J., Leggas, M., Relling, M., Egorin, M., Stewart, C., and Dyer, M.A. (2005) Topotecan combination chemotherapy in two new rodent models of retinobrastoma. Clin Cancer Res 11, 7569–7578.
Takeshita, F., Bader, A.G., Osaki, M., Takahashi, R., Yamamoto, Y., Kosaka, N., Kawamata, M., Kelnar, K., Brown, D., and Ochiya, T. (2010) Systemic delivery of miR-16 for RNAi therapy in prostate cancer. Mol Ther 18, 181–187.
Acknowledgements
This work was supported in part by a Grant-in-Aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control, a Grant-in-Aid for Scientific Research on Priority Areas Cancer from the Ministry of Education, Culture, Sports, Science and Technology, and the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio), and a Takeda Science Foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this protocol
Cite this protocol
Takeshita, F., Takahashi, Ru., Onodera, J., Ochiya, T. (2012). In Vivo Imaging of Oligonucleotide Delivery. In: Hoffman, R. (eds) In Vivo Cellular Imaging Using Fluorescent Proteins. Methods in Molecular Biology, vol 872. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-797-2_17
Download citation
DOI: https://doi.org/10.1007/978-1-61779-797-2_17
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-796-5
Online ISBN: 978-1-61779-797-2
eBook Packages: Springer Protocols